PHILIP GRAHAM: Open Payments
NPI 1922289107 · NORTH CHILI, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,243 in 90 payments from 17 companies in 2025. Trend: 2023 $779 · 2024 $1,683 · 2025 $2,243
Food & beverage: $2,243
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 23 | $799 |
| ABBVIE INC. | 32 | $628 |
| AstraZeneca Pharmaceuticals LP | 13 | $374 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Lilly USA, LLC | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Mannkind Corporation | 1 | $32 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| SANOFI PASTEUR INC. | 1 | $29 |
Products named: Ozempic, Wegovy, UBRELVY, AIRSUPRA, QULIPTA, VRAYLAR, FARXIGA, CAPLYTA.
Industry payments across NY — which companies pay providers there.
